Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -105,709 | -66,644 | -28,986 | -121,755 | -95,407 |
| Depreciation Amortization | -1,090 | -294 | 172 | 4,144 | 3,436 |
| Accounts receivable | 1,426 | 2,523 | -2,267 | 3,258 | 4,097 |
| Accounts payable and accrued liabilities | 2,682 | 5,963 | -686 | -4,634 | -8,555 |
| Other Working Capital | 1,816 | 3,047 | -13,966 | 6,789 | 3,433 |
| Other Operating Activity | 19,323 | 5,981 | 10,092 | 27,416 | 23,748 |
| Operating Cash Flow | $-81,552 | $-49,424 | $-35,641 | $-84,782 | $-69,248 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -7,690 | -5,539 | -3,156 | -2,125 | -688 |
| Purchase Of Investment | -267,274 | -90,627 | -67,375 | -171,446 | -162,714 |
| Sale Of Investment | 209,550 | 176,500 | 104,100 | 228,468 | 190,068 |
| Investing Cash Flow | $-65,414 | $80,334 | $33,569 | $54,897 | $26,666 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,208 | 2,008 | 1,126 | 21,262 | 18,331 |
| Other Financing Activity | 195,941 | -3,734 | -825 | -1,229 | -1,228 |
| Financing Cash Flow | $198,149 | $-1,726 | $301 | $20,033 | $17,103 |
| Beginning Cash Position | 47,962 | 47,962 | 47,962 | 57,814 | 57,814 |
| End Cash Position | 99,145 | 77,146 | 46,191 | 47,962 | 32,335 |
| Net Cash Flow | $51,183 | $29,184 | $-1,771 | $-9,852 | $-25,479 |
| Free Cash Flow | |||||
| Operating Cash Flow | -81,552 | -49,424 | -35,641 | -84,782 | -69,248 |
| Capital Expenditure | -7,690 | -5,539 | -3,156 | -2,125 | -688 |
| Free Cash Flow | -89,242 | -54,963 | -38,797 | -86,907 | -69,936 |